JMP Securities analyst Donald Ellis lowered his price target for Aerie Pharmaceuticals to $58 from $75 while reiterating an Outperform rating on the shares. Rhopressa and Rocklatan's scripts are experiencing "impressive growth," but a lower-than forecast average selling price warranted reduced fiscal 2020 estimates, Ellis tells investors in a research note. The analyst says that while Rhopressa's Medicare Part D uptake has been slower than expected, he expects to see an uptick in September and beyond, as patients reach deductibles and typical summer seasonality is in the past.